Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9688)	4/21/1999 1:25:00 AM
From: opalapril	Read Replies (2) \| Respond to of 17367

Greetings, George. I spent a few minutes reviewing the reorganized FAQ on the Xoma web site. It's tempting to conclude Xoma is finally coming clean with us, except of course that's what we thought before. Fool me once...etc. I still find it appalling and rather twisted that total number of deaths defines the end of the P-3. Together with the fact that since 1997 the DSMB has not found Neuprex efficacy strong enough to call a halt, even as late as its March 1999 meeting, there is ample reason for cautious investors to stay out of this stock altogether. Having already thrown caution to the wind, against my better judgment I decided to look again at the trauma, Mycoprex, and I-prex summaries even though, as I see it, Xoma stands or falls on Neuprex meningo results. Already plunged into a dark and ghoulish mood by re-reading the Neuprex P-3 trial standards, these 1998 statements about the trauma trial struck me: <<trial will enroll approximately 1650 patients with both blunt and penetrating trauma who received at least 2 units of blood within 12 hours of the original trauma>> <<We are already enrolling patients in the UK. We have considered Continental European sites, but for a variety of reasons, have not included any in the study>> Now that NATO, the U.S. Defense Department, the U.N., and every other international relief agency and its sister is crawling over Albania, Montenegro, Bosnia, Macedonia, Romania, etc., why not look for enrollment centers in the Balkans? Lord knows there are plenty of trauma cases there. If all we really need is 1650 patients, the P-3 could be over before Milosevic changes his underwear. On the other hand, maybe we don't want trial center clinics created where the ER personnel have to work in mud up to their armpits. Come to think of it, the snowy mountains of Kosovo may harbor lots of nasty meningo bugs useful for the Neuprex trial, too. Is it too late to enroll a Kosovar village or two full of dead people? Do you think that would that satisfy the FDA? Looks like Xoma made a big mistake moving to Bermuda. Should have moved to Dubrovnik instead.